827 related articles for article (PubMed ID: 28577748)
41. Prevalence, diagnostic value and clinical characteristics associated with the presence of circulating levels and renal deposits of antibodies against the M-type phospholipase A2 receptor in idiopathic membranous nephropathy.
Segarra-Medrano A; Jatem-Escalante E; Quiles-Pérez MT; Salcedo MT; Arbós-Via MA; Ostos H; Valtierra N; Carnicer-Cáceres C; Agraz-Pamplona I
Nefrologia; 2014 May; 34(3):353-9. PubMed ID: 24798555
[TBL] [Abstract][Full Text] [Related]
42. Primary membranous nephropathy in children and adolescents: a single-centre report from South Asia.
Ramachandran R; Nayak S; Kumar V; Kumar A; Agrawal N; Bansal R; Tiewsoh K; Nada R; Rathi M; Kohli HS
Pediatr Nephrol; 2021 May; 36(5):1217-1226. PubMed ID: 33108509
[TBL] [Abstract][Full Text] [Related]
43. Treatment of membranous nephropathy: time for a paradigm shift.
Ruggenenti P; Fervenza FC; Remuzzi G
Nat Rev Nephrol; 2017 Sep; 13(9):563-579. PubMed ID: 28669992
[TBL] [Abstract][Full Text] [Related]
44. Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal.
Rojas-Rivera JE; Carriazo S; Ortiz A
Clin Kidney J; 2019 Oct; 12(5):629-638. PubMed ID: 31583088
[TBL] [Abstract][Full Text] [Related]
45. [Treatment of idiopathic membranous nephropathy. Is the anti-CD20 antibody rituximab a reasonable option?].
Busch M; Gerth J; Ott U; Schip A; Haufe CC; Gröne HJ; Wolf G
Med Klin (Munich); 2008 Jul; 103(7):519-24. PubMed ID: 18604487
[TBL] [Abstract][Full Text] [Related]
46. Efficacy of leflunomide combined with prednisone for the treatment of PLA2R-associated primary membranous nephropathy.
Guo Y; Wu X; Liu L; Zhang H; Yang L; Chen W
Ren Fail; 2020 Nov; 42(1):122-130. PubMed ID: 31957527
[No Abstract] [Full Text] [Related]
47. Management of Membranous Nephropathy in Western Countries.
Alfaadhel T; Cattran D
Kidney Dis (Basel); 2015 Sep; 1(2):126-37. PubMed ID: 27536673
[TBL] [Abstract][Full Text] [Related]
48. Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up.
Zonozi R; Laliberte K; Huizenga NR; Rosenthal JK; Jeyabalan A; Collins AB; Cortazar FB; Niles JL
Am J Kidney Dis; 2021 Dec; 78(6):793-803. PubMed ID: 34174365
[TBL] [Abstract][Full Text] [Related]
49. From KDIGO 2012 towards KDIGO 2021 in idiopathic membranous nephropathy guidelines: what has changed over the last 10 years?
Stai S; Lioulios G; Christodoulou M; Papagianni A; Stangou M
J Nephrol; 2023 Mar; 36(2):551-561. PubMed ID: 36450999
[TBL] [Abstract][Full Text] [Related]
50. Response to immunosuppressive therapy in PLA
Wang J; Xie Q; Sun Z; Xu N; Li Y; Wang L; Liu S; Xue J; Hao CM
BMC Nephrol; 2017 Jul; 18(1):227. PubMed ID: 28693446
[TBL] [Abstract][Full Text] [Related]
51. Management of Membranous Nephropathy after MENTOR.
Trivin-Avillach C; Beck LH
Clin J Am Soc Nephrol; 2020 Mar; 15(3):415-417. PubMed ID: 31740571
[No Abstract] [Full Text] [Related]
52. Recent advances and prognosis in idiopathic membranous nephropathy.
Segal PE; Choi MJ
Adv Chronic Kidney Dis; 2012 Mar; 19(2):114-9. PubMed ID: 22449349
[TBL] [Abstract][Full Text] [Related]
53. How to Choose the Right Treatment for Membranous Nephropathy.
Peritore L; Labbozzetta V; Maressa V; Casuscelli C; Conti G; Gembillo G; Santoro D
Medicina (Kaunas); 2023 Nov; 59(11):. PubMed ID: 38004046
[TBL] [Abstract][Full Text] [Related]
54. A Proposal for a Serology-Based Approach to Membranous Nephropathy.
De Vriese AS; Glassock RJ; Nath KA; Sethi S; Fervenza FC
J Am Soc Nephrol; 2017 Feb; 28(2):421-430. PubMed ID: 27777266
[TBL] [Abstract][Full Text] [Related]
55. Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy.
van den Brand JAJG; Ruggenenti P; Chianca A; Hofstra JM; Perna A; Ruggiero B; Wetzels JFM; Remuzzi G
J Am Soc Nephrol; 2017 Sep; 28(9):2729-2737. PubMed ID: 28487395
[TBL] [Abstract][Full Text] [Related]
56. Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy.
Barbour SJ; Fervenza FC; Induruwage D; Brenchley PE; Rovin B; Hladunewich MA; Reich HN; Lafayette R; Aslam N; Appel GB; Zand L; Kiryluk K; Liu L; Cattran DC;
Clin J Am Soc Nephrol; 2023 Oct; 18(10):1283-1293. PubMed ID: 37471101
[TBL] [Abstract][Full Text] [Related]
57. Effect of rituximab in patients with PLA2R-associated membranous nephropathy and malignancy.
Guo Y; Ren M; Wang Y; Zhai Z; Yu L; Wang L; Tang L
Int Immunopharmacol; 2024 Jan; 126():111327. PubMed ID: 38056198
[TBL] [Abstract][Full Text] [Related]
58. Serum Levels of BAFF and APRIL Predict Clinical Response in Anti-PLA2R-Positive Primary Membranous Nephropathy.
Netti GS; Infante B; Spadaccino F; Godeas G; Corallo MG; Prisciandaro C; Croce L; Rotondi M; Gesualdo L; Stallone G; Grandaliano G; Ranieri E
J Immunol Res; 2019; 2019():8483650. PubMed ID: 31781684
[TBL] [Abstract][Full Text] [Related]
59. Primary membranous glomerulonephritis with negative serum PLA2R in haemophilia A successfully managed with rituximab - case report and review of the literature.
Meyer N; Cooper W; Kirwan P; Garsia R; Dunkley S; Gracey DM
BMC Nephrol; 2021 Jul; 22(1):268. PubMed ID: 34294065
[TBL] [Abstract][Full Text] [Related]
60. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.
Fervenza FC; Appel GB; Barbour SJ; Rovin BH; Lafayette RA; Aslam N; Jefferson JA; Gipson PE; Rizk DV; Sedor JR; Simon JF; McCarthy ET; Brenchley P; Sethi S; Avila-Casado C; Beanlands H; Lieske JC; Philibert D; Li T; Thomas LF; Green DF; Juncos LA; Beara-Lasic L; Blumenthal SS; Sussman AN; Erickson SB; Hladunewich M; Canetta PA; Hebert LA; Leung N; Radhakrishnan J; Reich HN; Parikh SV; Gipson DS; Lee DK; da Costa BR; Jüni P; Cattran DC;
N Engl J Med; 2019 Jul; 381(1):36-46. PubMed ID: 31269364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
